Deals

Lupin has collaborated with Alkem subsidiary Enzene Biosciences to launch the first ever cetuximab biosimilar in India. 

Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.

In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.

A settlement reached in US patent litigation over Janssen’s Stelara will allow Amgen to launch its ABP 654 ustekinumab biosimilar no later than 1 January 2025. It remains to be seen whether other ustekinumab developers will follow suit.

After a wave of big pharma interest in the biosimilars arena, originator enthusiasm for the sector appears to be waning – potentially opening up an opportunity for newcomers to compete on off-patent biologics.

Neuraxpharm has rebranded a Spanish finished dosage form facility to mark its “full integration” within the group, as it focuses on building its profile in Europe.

Alvotech has signed an agreement with Polifarma to distribute its proposed aflibercept biosimilar in Turkey. The compound, AVT06, is currently in the development stage.

Sandoz has made further preparations to bolster its biosimilars business ahead of its spinoff from parent company Novartis, announcing a development and manufacturing deal with Evotec at the same time as unveiling a further investment in its Holzkirchen site to transform it into a biotech development hub.

With EirGenix about to start Phase III trials for its proposed biosimilar version of Perjeta, the Taiwanese developer says it is negotiating with global firms for rights to the pertuzumab candidate.